
Opinion|Videos|January 22, 2026
The Trial Design and Interim Results From the GCAptAIN Trial
Advertisement
Episodes in this series

This video covers the following questions:
- Secukinumab, an IL‑17A inhibitor, emerged as a promising candidate for GCA based on Phase II data from last year showing 70% sustained remission at week 28 versus 20% with placebo (
Venhoff 2023 ). - Please share the results of Phase III GCAptAIN trial. How do you interpret these findings? (
Novartis Press Release )
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
New Antifibrotics Are Changing the Treatment Calculus in ILD
2
Q&A: Intensive LDL Lowering and Cardiovascular Prevention Strategies, With Lawrence Leiter, MD
3
Evaluating Clinical and Real-World Evidence in Hypercortisolism
4
2 Out of 3 Patients with Atopic Dermatitis Are Being Misdiagnosed
5























































































